Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and maintain remission. Treatment of CD typically begins with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) but often progresses to more-potent drugs, such as immunosuppressants and/or biologics. However, this scenario is changing, and more physicians are prescribing biologics as first-line therapy for recently diagnosed CD patients. Among the biologics, TNF-alpha inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) have a relatively constant patient share; however, newer biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara), especially Stelara, have witnessed a sharp increase in patient share.

QUESTIONS ANSWERED

  •  What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult CD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult CD patients?
  • How have Entyvio and Stelara been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of adult CD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of adult CD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Geographies

United States

Real World Data

Longitudinal patient-level claims data analysis

Key Drugs Covered

Humira, Remicade, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants

Key Analysis Provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.


Related Reports

Crohn's Disease - Landscape & Forecast - Disease Landscape & Forecast

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. T...

View Details

Crohn's Disease | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2020

Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. However, similar to adult CD, the primary goal of the treatment of pediatric CD is to induce...

View Details

Crohn's Disease - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Pediatric

Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. However, similar to adult

View Details